A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901-1962
- Rutgers - Robert Wood Johnson Medical School
-
-
New York
-
Rochester, New York, United States, 14642-0002
- University of Rochester School of Medicine and Dentistry
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women who are 18 years of age and older, as long as no vaginal atrophy is present. If vaginal atrophy is present, then topical hormone replacement can be provided for a minimum of 6 weeks and then she must be re-screened to be eligible,
- Greater than 3 continuous months of insertional (entryway) dyspareunia, pain to touch, or both with tampon insertion (modified 'Friedrich's Criteria', and
- an average pain level of "4" or greater on the 11-point tampon test (0 = no pain at all; 10 = worse pain ever) during the 2-week screening period must be exhibited.
(One tampon will be inserted each week). 4.) Must report pain with the "Tampon Insertion Pain" Test at visit 1
Exclusion Criteria:
- Other vulvar conditions, including dermatoses, vulvitis, vulvar papillomatosis, or atrophic vaginitis (presence of a maturation index)
- previous vestibulotomy
- active vaginal infection (positive Affirm ™ VPIII microbial identification test)
- pregnancy or at risk for pregnancy and not using a reliable birth control method for at least 3 months prior to entering the study
- any unstable medical condition, including renal impairment (creatinine clearance of ≤60 mL/min, BUN > 30mg/dL, serum creatinine > 2 mg/dL), significant hematological disease (leukopenia [WBC < 3.0 x 10-3µl, leukocytosis [WBC >20.0 x 10-3μl], neutropenia [ABS < 1.50 x 10-3 μl, <20%]), (thrombocytopenia [platelets < 100,000 μl], anemia [HCT < 27%, HBG <8 g/dL, RBC <3 x 10-6]), cardiovascular disease (cardiac conduction disturbance, CHF, hypertension [140/90]), hepatic insufficiency (serum AST, ALT, or ALP ≥ 3 times upper limit of normal), neurological disorder (seizures, syncopal episodes, peripheral neuropathy, severe pain other than that caused by vulvodynia), autoimmune disease, or respiratory illness
- psychiatric disorder, including history of major depressive disorder or substance abuse disorder within the past 6 months, a score of > 12 on the depression subscale of the Hospital Anxiety and Depression Scale (HADS), indicting a major depressive episode (35,36), a serious risk of suicide, or lifetime history of psychosis, hypomania or mania
- multiple allergies
- use of benzodiazepines, opiates, muscle relaxants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or CNS stimulants (including methylphenidate, amphetamine dextroamphetamine) within 2 weeks of randomization and during the study
- use of certain herbal agents within 2 weeks of randomization and during the study, including ginkgo biloba, evening primrose, St. John's Wort, Valerian, kava kava)
- topical lidocaine use
- Subjects, who are diagnosed with coexisting vaginismus, fibromyalgia and/or interstitial cystitis, must have greater vulvar pain than their coexisting conditions or they will not be eligible for study participation
- Subject who have previously taken gabapentin or Lyrica but discontinued the medication due to side effects are not eligible
- Subjects with active infections (Candida, BV, trichomonas, chlamydia, GC and HSV via Affirm/culture) must be treated and re-screened to eligible for participation
- Subjects with 10% or greater parabasal cells and/or vaginal atrophy can be provided with topical hormone replacement for a minimum of 6 weeks and then must be re-screened to be eligible
- Subjects who have had gastric bypass surgery are ineligible for study participation due to drug absorption problems
- HPV/abnormal Pap is not exclusionary
- Ongoing counseling and/or physical therapy is not exclusionary
- Subjects who report signs of mixed Vulvodynia (spontaneous/provoked, localized, generalized) during prescreening will not be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo oral capsule
Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
|
Placebo 2 capsules am and 3 capsules pm
Other Names:
Gabapentin 1200 mg am and 1800 mg pm
Other Names:
|
|
Active Comparator: Gabapentin
Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
|
Placebo 2 capsules am and 3 capsules pm
Other Names:
Gabapentin 1200 mg am and 1800 mg pm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tampon Test Pain Intensity
Time Frame: Week 6 for each treatment arm
|
Tampon pain on a 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever).
One tampon was inserted each week.
Tampon pain was assessed during last week of maintenance phase (7 days).
|
Week 6 for each treatment arm
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coital Pain
Time Frame: Week 6 of each treatment arm
|
Coital pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever), assessed after each sexual intercourse event.
The number of sexual intercourse events was averaged during final week of each treatment arm.
|
Week 6 of each treatment arm
|
|
Vulvodynia Pain
Time Frame: Week 6 for each treatment arm
|
Overall vulvodynia pain on an 11-point Numeric Rating Scale (0 = no pain at all; 10 = worse pain ever).
Pain was assessed daily during the last week of treatment.
Daily scores were averaged.
|
Week 6 for each treatment arm
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Candace S Brown, MSN, PharmD, University of Tennessee Health Science Center
- Principal Investigator: David C Foster, M.D., University of Rochester
- Principal Investigator: Gloria A Bachmann, M.D., Rutgers Robert Wood Johnson Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vulvar Diseases
- Vulvodynia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
Other Study ID Numbers
- 10-00985-FB CSBrown Vulvodynia
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.